New Study Using Aptar’s Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer’s Drug Directly to the Brain
AptarGroup, Inc. (ATR)
Last aptargroup, inc. earnings: 4/30 05:04 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.aptar.com
Company Research
Source: Business Wire
Research by Wake Forest University School of Medicine provides a crucial method for future Alzheimer’s disease treatment trials and reveals key differences in how the drug is absorbed in people with early cognitive decline CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university’s press release, the “groundbreaking” study confirms a vital step toward new Alzheimer’s treatments: intranasal insulin, delivered via nasal spray, safely and effectively reaches key memory regions of the brain in older adults. The study also revealed that people with early cognitive decline may absorb it differently.This research, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, describes th
Show less
Read more
Impact Snapshot
Event Time:
ATR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATR alerts
High impacting AptarGroup, Inc. news events
Weekly update
A roundup of the hottest topics
ATR
News
- AptarGroup CEO: China is unfazed by Trump's tariffs because their ‘grit and sheer willpower is on a different scale' [Yahoo! Finance]Yahoo! Finance
- AptarGroup, Inc. (NYSE:ATR) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? [Yahoo! Finance]Yahoo! Finance
- AptarGroup CEO: China is unfazed by Trump's tariffs because their ‘grit and sheer willpower is on a different scale' [Fortune]Fortune
- Nasus Pharma CEO Issues 2025 Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)Business Wire
ATR
Earnings
- 10/30/25 - Beat
ATR
Sec Filings
- 12/15/25 - Form 4
- 12/12/25 - Form 144
- 11/20/25 - Form 8-K
- ATR's page on the SEC website